Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Artiva Biotherapeutics develops off-the-shelf natural killer (NK) cell therapies targeting autoimmune diseases and cancers. Its lead candidate, AlloNK, enhances antibody-dependent cellular cytotoxicity (ADCC) in combination with B-cell targeted monoclonal antibodies, aiming to deplete pathogenic B-cells. The company focuses on scalable manufacturing, outpatient administration, and broad indications, leveraging proprietary processes and strategic collaborations to deliver accessible, safe, and effective cell therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.